How Poison Frogs Avoid Poisoning Themselves

Amphibians resist their own chemical defenses with amino acid modifications in the sequence for a target receptor.

Written byAbby Olena, PhD
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The phantasmal poison frog, Epipedobates anthonyi, is the original source of epibatidine, discovered by John Daly in 1974. In fact, epibatidine is named for frogs of this genus. Epibatidine has not been found in any animal outside of Ecuador, and its ultimate source, proposed to be an arthropod, remains unknown. This frog was captured at a banana plantation in the Azuay province in southern Ecuador in August 2017.REBECCA TARVIN

Poison frogs become poisonous by isolating chemicals from their food and storing them in their skin. One such compound, epibatidine, is a stronger painkiller than morphine, but has not been tested in humans because even low doses are deadly to rodents. But for the frogs themselves, this powerful neurotoxin is totally impotent.

According to a study published today (September 21) in Science, several groups of epibatidine-bearing frogs have independently evolved amino acid changes in the toxin’s target, the nicotinic acetylecholine receptor. These modifications allow the amphibians to escape self-toxicity, yet preserve the receptor’s ability to bind the neurotransmitter acetylcholine.

The authors “show DNA sequence changes [and] amino acid sequence changes that have happened multiple times in multiple lineages of frogs,” says Joel McGlothin, an evolutionary ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • abby olena

    As a freelancer for The Scientist, Abby reports on new developments in life science for the website. She has a PhD from Vanderbilt University and got her start in science journalism as the Chicago Tribune’s AAAS Mass Media Fellow in 2013. Following a stint as an intern for The Scientist, Abby was a postdoc in science communication at Duke University, where she developed and taught courses to help scientists share their research. In addition to her work as a science journalist, she leads science writing and communication workshops and co-produces a conversational podcast. She is based in Alabama.  

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies